^
Association details:
| Biomarker: | FGFR2-SORBS1 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
Excerpt:
...a 74-year-old female with recurrent FGFR2-SORBS1 fusion-positive ICC metastatic to her liver and lymph nodes...On third-line BGJ398 treatment, she achieved a maximum response of −68% followed by progression of all three liver lesions at approximately 12 months.
DOI:
https://dx.doi.org/10.1158%2F2159-8290.CD-19-0182
